Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.
about
Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.Cytotoxic effects of betaxolol on healthy corneal endothelial cells both in vitro and in vivo.Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial.A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma.Cod liver oil: a potential protective supplement for human glaucoma.Selective Laser Trabeculoplasty: A Clinical Review.Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?How ocular surface disease impacts the glaucoma treatment outcomeThe prevalence of glaucoma in patients undergoing surgery for eyelid entropion or ectropion.In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure.Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.Safety of carbonic anhydrase inhibitors.The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.Ocular surface disease in patients under topical treatment for glaucoma.Anomalies in drug choice in glaucoma clinics.Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent.Ocular surface - a complex and vulnerable adoptive environment for topical glaucoma treatment.Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells.A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controll
P2860
Q34981291-DF364009-D0C6-4DD3-8BE2-7E8B9A4BB46EQ35122238-9F802F90-30B3-4B75-BDAD-F754BF06DA8CQ35822206-04F722D3-0699-4C04-86D4-2AE6B2A23004Q35906365-D6657410-A89D-4B83-9032-6DCFFC8B8F11Q35924130-43326A04-1629-4CB9-8E06-001E67495496Q35964395-BF62B728-CA20-42AB-BD56-12BE080A2359Q36134942-59AAD499-91B6-4F02-AD34-F4AAA8554471Q37242107-CB74E6A4-91B9-482F-AD21-4783A76E752EQ37259818-156CAB9D-919E-4169-B4D8-3C0920EC5778Q37343999-5CFED292-E2C8-4B7C-BB26-F85E9F5287F9Q37690470-DFA357EA-AF59-4AA8-B5FF-8FB18CE3B33CQ37690494-AB441D38-4952-4758-9E49-ACA44FBE8DE5Q38168361-56E106B4-6758-4731-A19A-7D70A957A073Q38194570-FA70A12E-CFE5-4FF5-94EF-64DEEB45DACBQ39096598-50FF641C-A1D0-478C-B3B6-5F5F41B969A9Q40204404-88904A6E-9BAE-4D5F-B3EA-C4F40486A725Q42692962-630B22C1-CB59-48F6-95AE-E0C9EC1E42BDQ46885910-ED2BFD99-0D3F-4E10-9AA7-7BC63892235AQ47170651-39E61D66-151E-4ED5-A619-00A8F6506E74Q49923423-0435E371-0D4D-487C-AFD1-7466818EDEE0Q54987431-CED72F90-4222-4003-AB00-10995DA3D728Q55375940-B3D78B3F-7CCB-42C6-9386-D2B83A805F06
P2860
Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of common topical anti ...... yelids and periorbital tissue.
@en
Effects of common topical anti ...... yelids and periorbital tissue.
@nl
type
label
Effects of common topical anti ...... yelids and periorbital tissue.
@en
Effects of common topical anti ...... yelids and periorbital tissue.
@nl
prefLabel
Effects of common topical anti ...... yelids and periorbital tissue.
@en
Effects of common topical anti ...... yelids and periorbital tissue.
@nl
P2860
P1433
P1476
Effects of common topical anti ...... eyelids and periorbital tissue
@en
P2093
C Robert Bernardino
P2860
P304
P356
10.2165/11588830-000000000-00000
P577
2011-04-01T00:00:00Z